In this interview from the ASRS 2014 Annual Meeting, Dr. Thomas Stone discusses major highlights from the 2014 Preferences and Trends (PAT) Survey. More than 800 members of ASRS participated in the 16th annual survey. ASRS also separately surveyed members of 25 international retina societies and received more than 660 responses. The combined results showed the relative popularity of bevacizumab (Avastin) for the treatment of wet age-related macular degeneration (AMD), despite the fact that most respondents believe aflibercept (Eylea) to be more effective. Dr. Stone also discusses the declining use of a lid speculum for intravitreal injections, the evolving role for focal grid laser and scleral buckling, and international differences in the use of a treat-and-extend protocol for AMD.